Shanghai Runda Medical Technology Co.Ltd(603108) it was announced that recently, Huizhong biology, a wholly-owned subsidiary of the company, signed a strategic cooperation and joint venture agreement with aosenduo biology, a wholly-owned subsidiary of aosenduo in China, to establish a joint venture with a registered capital of RMB 2 million. The company plans to invest RMB 1 million with its own capital, accounting for 50% of the registered capital of the joint venture. The joint venture will develop in vitro diagnostic reagent products that meet the needs of the Chinese market for Orson Vitros immunodiagnostic analyzer (including but not limited to Orson Vitros 3600, 5600 and 7600 instruments). All intellectual property rights in any form formed in the research and development process belong to the joint venture. At the same time, the company will provide its own production capacity and product promotion channels to meet the needs of entrusted production and product promotion of the joint venture.
© China Stock Market News